Back to Results
First PageMeta Content
Lipid storage disorders / Lysosomal Acid Lipase Deficiency / Wolman disease / Cholesteryl ester storage disease / Orphan drug / Hunter syndrome / Clinical trial / Cirrhosis / Sanfilippo syndrome / Health / Rare diseases / Medicine


The people. Their lives. The impact[removed]Annual Report Dear Fellow Shareholders, 2013 was an amazing year for both Synageva and for patients. We met,
Add to Reading List

Document Date: 2014-04-23 16:54:16

Open Document

File Size: 954,86 KB

Share Result on Facebook

City

Lexington / /

Company

Nasdaq Global Select Market Securities / The NASDAQ Stock Market LLC / 1934 SYNAGEVA BIOPHARMA CORP. / Synageva BioPharma Corp. / Eurordis / LAL Solace / LAL Deficiency / Laboratory Corporation of America Holdings / CLIMB / /

Continent

Europe / South America / /

Country

Japan / United States / /

Currency

USD / /

Event

General or Shareholder Meeting / FDA Phase / Company Expansion / /

Facility

Mine Safety Disclosures / /

IndustryTerm

therapies for a variety of diseases / manufacturing facility / therapy for a lysosomal storage disease / consolidated subsidiaries / ultra-rare products / therapies for life-threatening rare diseases / therapies for patients with lifethreatening rare diseases / access to our products / manufacturing facilities / therapies for lysosomal storage diseases / manufacturing platform / corporate Web site / manufacturing capabilities / medical affairs infrastructure / clinical study protocol / biopharmaceutical / production technology / manufacturing / therapeutic products / commercialscale manufacturing facility / manufacturing platforms / /

MedicalCondition

rare and devastating diseases / Commercialization LAL Deficiency / rare diseases / central line infections / another devastating lysosomal storage disease / mucopolysaccharidosis / rare systemic disease / liver failure / LAL Deficiency Disease Overview LAL Deficiency / additional rare disease / lysosomal acid lipase deficiency / cirrhosis / cholecystitis/cholelithiasis / Cholesteryl Ester Storage Disease / disorder / Liver Dysfunction Due to LAL Deficiency / tachycardia / lysosomal storage disease / diarrhea / liver disease / LAL Deficiency / common diseases / several other rare disease / ultra-rare disorder / chronic conditions / mucopolysaccharidoses / Adult Subjects With LAL Deficiency / mucopolysaccharidosis IIIB / accelerated atherosclerosis / disease / specific rare disease / Rare disease / non-alcoholic fatty liver disease / dyslipidemia / fever / Growth Failure Due to LAL Deficiency / portal hypertension / Wolman disease / diseases / lysosomal storage diseases / aggressive liver disease / Deficiency / advanced liver disease / fibrosis / /

MedicalTreatment

enzyme replacement therapies / antibiotics / liver transplant / enzyme replacement therapy / /

MusicAlbum

South America / /

Organization

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington / D.C. / U.S. Food & Drug Administration / European Medicines Agency / U.S. Food and Drug Administration / National Organization for Rare Disorders / I.R.S. / European Union / Securities and Exchange Commission / Ministry of Health / /

Person

MPS IIIB / /

/

Position

independent investigator / physician / Principal Accountant / Director Independence / focused physician / Sanj K. Patel President and Chief Executive Officer / Principal Executive / /

Product

Sebelipase Alfa / other investigational new drug / Japan / EMA / Animal Drug / /

ProvinceOrState

Delaware / Georgia / Massachusetts / /

PublishedMedium

Natural History / /

Region

Asia Pacific / /

Technology

alpha / antibodies / transplantation / production technology / two clinical study protocol / drug development / /

SocialTag